Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2025-08-01 Earnings Release
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for the first quarter ended June 30, 2025. It includes revenue, EBITDA, PAT, margins, cash flow, and management commentary on performance and outlook. The document references Q1FY26 financial results and provides detailed financial metrics and operational highlights. It is not a full quarterly report but an initial announcement of quarterly financial results. The document is about 5,834 characters, which is consistent with a press release length. Therefore, this fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Q1 2026
2025-08-01 English
Allotment of Securities
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing them about the allotment of equity shares under an Employee Stock Option Scheme. It details the number of shares allotted and the consequent increase in paid-up share capital. There is no financial data, report, or analysis included. The document is an announcement of a capital change event (share allotment) rather than a full report or financial statement. The document length is short (2393 characters), and it serves as a notification to the exchanges about the share allotment. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2025-08-01 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document contains an Independent Auditor’s Review Report on Unaudited Quarterly Financial Results for the quarter ended 30 June 2025. It references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting. The presence of unaudited quarterly financial results and the auditor's review report indicates this is an Interim / Quarterly Report. The document length is 7105 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2025-08-01 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding an update on the USFDA inspection of a manufacturing facility. It mentions the issuance of an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) classification. The letter is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically covers material event disclosures. The document is short (1753 characters) and serves as an announcement of a regulatory inspection outcome rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-07-26 English
Shareholders meeting
Regulatory Filings
2025-07-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter from the company to stock exchanges announcing the date and details of an upcoming earnings call for Q1 FY2025-26 financial performance. It includes dial-in numbers and contact information for clarifications. There is no actual financial data or results presented, only an invitation to the earnings call. This matches the definition of a Call Transcript (CT) document type, which includes full text transcripts of company conference calls. However, since this is only an invitation to the earnings call and not the transcript itself, it is not a CT. It is also not an Earnings Release (ER) because it does not contain financial highlights or results. The document is an announcement of the earnings call event, which is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other categories and is under 5,000 characters. Therefore, the correct classification is Regulatory Filings (RNS).
2025-07-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.